The global prevalence of overweight and obesity is rising at an alarming rate. The same, however, cannot be said about drugs used for treating these indications. Whereas rates of obesity and overweight have increased continuously over the past 50 years, the market for drugs against such indications has only seen failures till date, says “Booming Global Obesity Drug Marketâ€, our new market research report.
According to the report, currently four drugs dominate this market. They are Roche’s Xenical, Abbots Meridia, Sanofi’s Acomplia and GSK’S Alli. All these drugs either suffer from unacceptable side effects or just fail to provide the desired weight loss that consumers had expected from them. Moreover, the biggest hurdle for these drugs is the fact that obesity is still regarded as a lifestyle disorder by most health officials and, as a result, drugs treating obesity doesn’t qualify for reimbursement. Since the price of these drugs can range anywhere between US$ 50 and US$ 200, patients often discontinue after they fail to give the desired results.
Despite its previous failures, however, the future potential for obesity drugs is huge. The future pipeline for obesity drugs is rich with a number of drugs in late phase-II and Phase-III pipelines. With no effective weight loss therapy currently available in the market and the number of overweight and obese patients expected to reach 2 Billion and 600 Million respectively by 2012, the opportunity is tremendous. And if any drug with a high benefit to risk ration manages to reach the market, it will easily become a potential blockbuster.
“Booming Global Obesity Drug Market†is an extensive and objective analysis on the global market for obesity drugs. It investigates both the past and current trends in the global obesity market, and outlines the future trends shaping the industry. It comprehensively assesses the performance of drugs, both in the market and in developing stage.
Based on various present and future indicators, the report evaluates future outlook and performance of key products in the industry. It can thus give valuable information for manufacturers/investors preparing to enter the market for obesity drugs.
About RNCOS:
RNCOS, incorporated in the year 2002, is an industry research firm. We are a team of industry experts who analyze data collected from credible sources. We provide industry insights and analysis that helps corporations to take timely and accurate business decision in today’s globally competitive environment.
We are running a special offer on select reports till Year end, where you can avail our reports at discounted prices. Please click here to know more: http://www.rncos.com/promotion.htm
For more information visit: http://www.rncos.com/Report/IM166.htm
Current Industry News: http://www.rncos.com/Blog/
